Neohalo Biosciences
Hangzhou Neohalo Biotechnology Co., Ltd. is a wholly-owned subsidiary of Hong Kong Stock Exchange listed company Novartis Health (6606. HK). It was established in April 2022 and is located in the Zhejiang Pilot Free Trade Zone in China. Xinhui Biotechnology is a reagent and instrument platform supplier specializing in upstream nucleic acid research, mainly engaged in the development and promotion of nanomaterials and biochip products, and serving public health and life sciences through this. The company is particularly committed to developing internationally leading free RNA (cfRNA) research related reagents and equipment. Currently, it has launched a trace small RNA separation and purification kit based on silicon magnetic polymer (SMAGG) patent technology and a trace small RNA library construction kit based on connector self linking product removal patent technology. In the future, it will also launch a digital microfluidic technology platform based on the principle of dielectric electrowetting. In addition, the company also has a 100000 level clean production workshop in Hangzhou, which ensures the stable and reliable quality of the developed products to the greatest extent, and helps the rapid development of the application field of cfRNA detection.
-
R&D Capability
R&D Capability
Neohalo Biosciences focuses on developing industry-leading original detection technologies to serve public health and life sciences
-
Patent system
Patent system
Micro small RNA isolation and purification products based on patented nano magnetic bead technology and micro small RNA library construction products based on patented joint self linking product removal technology.
-
Platform construction
Platform construction
The company also has a 100000 level clean production workshop in Hangzhou, ensuring the stable and reliable quality of the developed products to the greatest extent, and assisting in the rapid development of small RNA detection applications.